Bioventus Inc.: updates and filings

BVSNASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$10.46

November 16, 2026Market cap $697M

What Ploutos Investor adds for Bioventus

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 80 daysAround Feb 5, 2027 · for Q4 2026

last Nov 2, 2026next Feb 5, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 5, 2026 latest annualNov 2, 2026 latest quarterly
  • Nov 13, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 2, 2026Quarterly reportfor the period to Sep 26, 2026
    Form10-Q
  • Nov 2, 2026Results of operations
    Form8-K
  • Oct 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 5, 2026Quarterly reportfor the period to Jun 27, 2026
    Form10-Q
  • Aug 5, 2026Results of operations, other material events
    Form8-K
  • Jul 27, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jun 4, 2026Shareholder vote
    Form8-K
  • May 29, 2026Conflict minerals report
    FormSD
  • May 21, 2026Regulation FD disclosure
    Form8-K
  • May 6, 2026Quarterly reportfor the period to Mar 28, 2026
    Form10-Q
  • May 6, 2026Results of operations
    Form8-K
  • Apr 22, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 22, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 22, 2026Annual meeting proxy statement
    FormDEF 14A
  • Mar 5, 2026Shares registered for employees
    FormS-8
  • Mar 5, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 5, 2026Results of operations
    Form8-K
  • Feb 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 17, 2025Officer or director change
    Form8-K
  • Nov 4, 2025Quarterly reportfor the period to Sep 27, 2025
    Form10-Q
  • Nov 4, 2025Results of operations
    Form8-K
  • Aug 14, 2025Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 6, 2025Quarterly reportfor the period to Jun 28, 2025
    Form10-Q
  • Aug 6, 2025Results of operations
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 19, 2016.

The full analysis

What do Bioventus's filings show?

The filings are where every one of Bioventus's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.